Company Filing History:
Years Active: 2006
Title: Claes Wadelius: Innovator in Genetic Research
Introduction
Claes Wadelius is a prominent inventor based in Upsala, Sweden. He has made significant contributions to the field of genetics, particularly in understanding macular dystrophy. His work has implications for both research and clinical diagnostics.
Latest Patents
Wadelius holds a patent related to Best's macular dystrophy gene. This patent includes novel human and mouse DNA sequences that encode the gene CG1CE. When mutated, this gene is responsible for Best's macular dystrophy. The patent provides genomic CG1CE DNA as well as cDNA that encodes the CG1CE protein. Additionally, it outlines methods for expressing the CG1CE protein in recombinant systems and diagnostic methods to detect patients with mutant CG1CE genes. He has 1 patent to his name.
Career Highlights
Wadelius has had a distinguished career, working with leading organizations in the field of genetics. He is currently associated with Merck & Co., Inc., where he continues to advance research in genetic disorders. His expertise has been instrumental in developing innovative solutions for genetic diagnostics.
Collaborations
Throughout his career, Claes Wadelius has collaborated with notable colleagues, including Konstantin Petrukhin and C. Thomas Caskey. These collaborations have further enriched his research and contributed to advancements in the understanding of genetic conditions.
Conclusion
Claes Wadelius is a key figure in genetic research, particularly in the study of macular dystrophy. His innovative work and collaborations have made a lasting impact in the field.